LPCN

SEC filing LPCN Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

14d ago

SEC filing LPCN Reports $24.7M Cash, $3.7M Net Loss, $119K Royalty, Phase 3 PPD Trial Misses Primary Endpoint

26d ago

SEC filing LPCN Announces Chairman Change, Papapetropoulos Resigns, Ono Appointed Chairman, Compensation Committee Update

41d ago

Insider trade Purchase by John W. Higuchi

55d ago

Insider trade Purchase by Mahesh V. Patel (Chief Executive Officer)

56d ago

Insider trade Purchase by John W. Higuchi

56d ago

SEC filing LPCN Posts $14.9M Cash, $9.6M Net Loss; Advances LPCN 1154 PPD Phase 3, LPCN 2201 MDD, LPCN 2101 Epilepsy, LPCN 2401 Obesity, TLANDO Partnerships

84d ago

SEC filing LPCN Announces $50M Equity Offering via Sales Agreement with A.G.P. Alliance, Dorsey & Whitney Legal Opinion Filed

89d ago

SEC filing LPCN Updates Corporate Presentation, Files Exhibit 99.1

104d ago

Scanner Unusual volume (2.5x average)

124d ago

News Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

133d ago

News Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

141d ago

SEC filing LPCN Hits 80% Enrollment in Phase 3 PPD Trial, Topline Results Planned Q2 2026

168d ago

SEC filing LPCN Director Jeffrey Fink Resigns, Board to Initiate Search for Replacement

168d ago